DK2943189T3 - Mitoguazon til behandling af progressiv multipel sklerose - Google Patents
Mitoguazon til behandling af progressiv multipel sklerose Download PDFInfo
- Publication number
- DK2943189T3 DK2943189T3 DK14737914.3T DK14737914T DK2943189T3 DK 2943189 T3 DK2943189 T3 DK 2943189T3 DK 14737914 T DK14737914 T DK 14737914T DK 2943189 T3 DK2943189 T3 DK 2943189T3
- Authority
- DK
- Denmark
- Prior art keywords
- mitoguazone
- treatment
- multiple sclerosis
- progressive multiple
- progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750336P | 2013-01-08 | 2013-01-08 | |
US201361823276P | 2013-05-14 | 2013-05-14 | |
PCT/US2014/010714 WO2014110154A1 (en) | 2013-01-08 | 2014-01-08 | Methods and comp0stions for treatment of demyelinating diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2943189T3 true DK2943189T3 (da) | 2021-04-06 |
Family
ID=51167347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14737914.3T DK2943189T3 (da) | 2013-01-08 | 2014-01-08 | Mitoguazon til behandling af progressiv multipel sklerose |
Country Status (12)
Country | Link |
---|---|
US (2) | US10085955B2 (da) |
EP (2) | EP2943189B1 (da) |
JP (2) | JP6370804B2 (da) |
CN (2) | CN109432073A (da) |
AU (2) | AU2014205529B2 (da) |
BR (1) | BR112015016189A8 (da) |
CA (1) | CA2896977C (da) |
DK (1) | DK2943189T3 (da) |
ES (1) | ES2859553T3 (da) |
HK (1) | HK1217451A1 (da) |
IL (1) | IL239851B (da) |
WO (1) | WO2014110154A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3228310B1 (en) | 2007-03-09 | 2021-05-05 | Pathologica LLC | Methylglyoxal bis(guanyl-hydrazone) for regulating osteopontin in a subject |
EP3473247A1 (en) | 2009-07-16 | 2019-04-24 | Pathologica LLC | Composition for oral delivery comprising mgbg for use in treating multiple sclerosis |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
PL2665471T3 (pl) | 2011-01-19 | 2018-06-29 | Pathologica, Llc. | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg |
CN109432073A (zh) | 2013-01-08 | 2019-03-08 | 帕萨罗杰卡有限公司 | Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 |
US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
WO2017042274A1 (en) * | 2015-09-08 | 2017-03-16 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Quinoline derivates for use in treating leukodystrophy and treatment method |
CA3016391A1 (en) * | 2016-03-07 | 2017-09-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Sustained drug release sheet for treating nerve injury |
US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
KR20200143716A (ko) * | 2018-04-13 | 2020-12-24 | 모데차이 체비온 | 탈수초 치료용 조성물 및 방법 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4201788A (en) | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
US5614557A (en) | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US4520031A (en) | 1981-06-01 | 1985-05-28 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
DE69733207T2 (de) | 1996-09-13 | 2006-02-02 | University of Florida Research Foundation, Inc., Gainesville | Verfahren zur hemmung von elf5a-biosynthese |
AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
US6172261B1 (en) | 1997-07-15 | 2001-01-09 | Oridigm Corporation | Polyamine analogues as therapeutic and diagnostic agents |
US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
US6169115B1 (en) | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
ATE335719T1 (de) | 1999-04-30 | 2006-09-15 | Cellgate Inc | Polyamine und ihre therapeutische verwendung |
US6544541B1 (en) * | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
CN1221281C (zh) * | 2000-02-18 | 2005-10-05 | 耶达研究与开发有限公司 | 共聚物1的口服、鼻部和肺部用剂型 |
EP1337504A4 (en) | 2000-11-08 | 2005-10-05 | Cellgate Inc | NOVEL AMINO ACID CONJUGATES AND POLYAMINE ANALOGUES USEFUL AS ANTICANCING AGENTS |
US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
EP1373185B1 (en) | 2001-01-08 | 2017-03-01 | Aminex Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
WO2003013609A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
WO2003013245A1 (en) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
CA2454879A1 (en) | 2001-08-15 | 2003-02-27 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
US7211602B2 (en) * | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
US7282490B2 (en) * | 2001-11-21 | 2007-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
US20060160087A1 (en) | 2003-01-31 | 2006-07-20 | Mcgrath Michael | Monitoring and treatment of amyotrophic lateral sclerosis |
RU2358716C2 (ru) | 2003-04-08 | 2009-06-20 | Новартис Аг | Органические соединения |
RU2375048C2 (ru) | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
WO2005041988A1 (en) | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
EP1730100A1 (en) | 2004-03-29 | 2006-12-13 | MediQuest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
US7445794B1 (en) | 2004-04-29 | 2008-11-04 | The Regents Of The University Of Colorado | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors |
JP2008528616A (ja) * | 2005-01-28 | 2008-07-31 | ザンサス ファーマシューティカルズ, インコーポレイテッド | 炎症性疾患および脱髄性疾患を処置するための化合物 |
AU2006275679B2 (en) | 2005-07-29 | 2012-04-12 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
US11744803B2 (en) | 2005-07-29 | 2023-09-05 | Stichting Groningen Centre for Drug Rese | PH-controlled pulsatile delivery system, methods for preparation and use thereof |
CA2623203C (en) | 2005-09-23 | 2014-08-12 | Pathologica, Llc | Methods for treating viral infections using polyamine analogs |
WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
JP4929505B2 (ja) | 2006-10-31 | 2012-05-09 | Idec株式会社 | リレーソケット |
EP2164698A1 (en) | 2007-03-09 | 2010-03-24 | Sustainable Solutions, Inc. | Regenerated cotton board material and method of manufacture |
EP3228310B1 (en) | 2007-03-09 | 2021-05-05 | Pathologica LLC | Methylglyoxal bis(guanyl-hydrazone) for regulating osteopontin in a subject |
WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
WO2009018368A1 (en) | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US20110195049A1 (en) | 2008-10-13 | 2011-08-11 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
JP2012511519A (ja) | 2008-12-10 | 2012-05-24 | アンフイ ジョンレン テクノロジー コーポレイション,リミテッド | 制御放出組成物 |
US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
EP3473247A1 (en) | 2009-07-16 | 2019-04-24 | Pathologica LLC | Composition for oral delivery comprising mgbg for use in treating multiple sclerosis |
EP2283830A1 (en) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
PL2665471T3 (pl) | 2011-01-19 | 2018-06-29 | Pathologica, Llc. | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg |
EP3502236B1 (en) * | 2011-02-18 | 2023-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
CN109432073A (zh) | 2013-01-08 | 2019-03-08 | 帕萨罗杰卡有限公司 | Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 |
-
2014
- 2014-01-08 CN CN201811424556.8A patent/CN109432073A/zh active Pending
- 2014-01-08 US US14/759,599 patent/US10085955B2/en active Active
- 2014-01-08 ES ES14737914T patent/ES2859553T3/es active Active
- 2014-01-08 JP JP2015551862A patent/JP6370804B2/ja not_active Expired - Fee Related
- 2014-01-08 CA CA2896977A patent/CA2896977C/en active Active
- 2014-01-08 BR BR112015016189A patent/BR112015016189A8/pt not_active Application Discontinuation
- 2014-01-08 AU AU2014205529A patent/AU2014205529B2/en not_active Ceased
- 2014-01-08 EP EP14737914.3A patent/EP2943189B1/en active Active
- 2014-01-08 WO PCT/US2014/010714 patent/WO2014110154A1/en active Application Filing
- 2014-01-08 CN CN201480007129.3A patent/CN105163730B/zh not_active Expired - Fee Related
- 2014-01-08 DK DK14737914.3T patent/DK2943189T3/da active
- 2014-01-08 EP EP21152182.8A patent/EP3831372A1/en not_active Withdrawn
-
2015
- 2015-07-08 IL IL239851A patent/IL239851B/en active IP Right Grant
-
2016
- 2016-05-17 HK HK16105632.5A patent/HK1217451A1/zh unknown
-
2018
- 2018-07-10 JP JP2018130715A patent/JP2018172427A/ja active Pending
- 2018-08-23 US US16/109,824 patent/US10350178B2/en not_active Expired - Fee Related
- 2018-10-15 AU AU2018247351A patent/AU2018247351B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2014205529B2 (en) | 2018-08-09 |
EP2943189A4 (en) | 2016-07-06 |
CA2896977A1 (en) | 2014-07-17 |
US20180360783A1 (en) | 2018-12-20 |
CN105163730A (zh) | 2015-12-16 |
CA2896977C (en) | 2021-12-07 |
JP2018172427A (ja) | 2018-11-08 |
JP6370804B2 (ja) | 2018-08-08 |
WO2014110154A1 (en) | 2014-07-17 |
US20150359761A1 (en) | 2015-12-17 |
JP2016504389A (ja) | 2016-02-12 |
AU2014205529A1 (en) | 2015-07-09 |
EP3831372A1 (en) | 2021-06-09 |
NZ749754A (en) | 2020-09-25 |
CN105163730B (zh) | 2018-10-30 |
IL239851A0 (en) | 2015-08-31 |
HK1217451A1 (zh) | 2017-01-13 |
IL239851B (en) | 2020-07-30 |
US10085955B2 (en) | 2018-10-02 |
NZ709157A (en) | 2020-09-25 |
BR112015016189A8 (pt) | 2019-10-22 |
US10350178B2 (en) | 2019-07-16 |
AU2018247351B2 (en) | 2020-04-09 |
CN109432073A (zh) | 2019-03-08 |
ES2859553T3 (es) | 2021-10-04 |
BR112015016189A2 (pt) | 2017-07-11 |
EP2943189A1 (en) | 2015-11-18 |
AU2018247351A1 (en) | 2018-11-08 |
EP2943189B1 (en) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2943189T3 (da) | Mitoguazon til behandling af progressiv multipel sklerose | |
DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
DK2940999T3 (da) | Fremgangsmåde til entropiafkodning af skivesegmenter | |
DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3062811T3 (da) | Angiopoietin-baserede interventioner til behandling af cerebral malaria | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
DK2976359T4 (da) | Fremgangsmåder til behandling af osteogenesis imperfecta | |
DK3021839T3 (da) | Sammensætninger for behandling af fibrose | |
DK3003366T3 (da) | På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider | |
GB201616211D0 (en) | Prediction of adverse drug events | |
DK2992104T3 (da) | Fremgangsmåde til ekspression | |
DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
DK2906580T3 (da) | Behandling af amyotrofisk lateral sklerose | |
DK2777689T3 (da) | Ny farmaceutisk sammensætning til behandling af svampeinfektioner | |
DK3065790T3 (da) | Fremgangsmåder til fjernelse af alpha-galactose | |
ITUA20161318A1 (it) | Assieme di componenti elettrici di bicicletta | |
DK2964381T3 (da) | Sammensætning til fremstilling af silikonegummimasser | |
DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner |